Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

23 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

11 Jul 2024 00:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

09 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Half-year statement of IPSEN liquidity agreement - 2024 06 30

08 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

02 Jul 2024 00:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

25 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

18 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

11 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

10 Jun 2024 15:54:20 By Nasdaq GlobeNewswire

Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

07 Jun 2024 00:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   

06 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    

05 Jun 2024 01:00:00 By Nasdaq GlobeNewswire

Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

03 Jun 2024 00:00:00 By Nasdaq GlobeNewswire

Ipsen announces the launch of an employee shareholding plan

30 May 2024 11:15:00 By Nasdaq GlobeNewswire

Annual General Meeting of Ipsen S.A. held on 28 May 2024

28 May 2024 11:00:00 By Nasdaq GlobeNewswire

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

28 May 2024 00:00:00 By Nasdaq GlobeNewswire